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Abstract: Deletions of the 15q26 region encompassing the chromodomain helicase DNA binding 
domain 2 (CHD2) gene have been associated with intellectual disability, behavioral problems, 
and several types of epilepsy. Including the cases mentioned in ECARUCA (European cytoge-
neticists association register of unbalanced chromosome aberrations) and DECIPHER (database 
of genomic variation and phenotype in humans using ensembl resources), so far, a total of 13 
intellectually disabled patients with a genetically proven deletion of the CHD2 gene are described, 
of whom eleven had a history of severe forms of epilepsy starting from a young age. In this article, 
a moderately intellectually disabled 15-year-old male with a 15q26.1–q26.2 interstitial deletion is 
reported, who was referred for analysis of two recent short-lasting psychotic episodes that were 
nonresponsive to antipsychotic treatment and recurrent disinhibited behaviors since early infancy. 
Careful interdisciplinary assessment revealed that the psychotic phenomena originated from a 
previously unrecognized absence epilepsy. Treatment with valproic acid was started which resulted 
in full remission of psychotic symptoms, and consequently, substantial improvement of behavior. 
It was concluded that in case of (rare) developmental disorders with genetically proven etiology, 
a detailed inventory of anamnestic data and description of symptomatology over time may elucidate 
epilepsy-related psychopathology for which a specific treatment regimen is needed.
Keywords: 15q26.1 interstitial deletion, CHD2 gene, intellectual disability, epilepsy, psychotic 
disorder, neuropsychology
Introduction
Microarray analysis has been shown to be of crucial importance for the understanding 
of the genetic etiology of intellectual disability (ID). With this technique, numerous 
(de novo) copy number variations have been discovered leading to several circum-
scribed microdeletion syndromes.1,2 Especially in patients in whom neuropsychiatric 
disorders or congenital anomalies are present, in addition to ID, extensive genetic 
analysis is warranted.
Partial deletions of the long arm of chromosome 15, particularly in the 15q26 
region, have been typically associated with somatic anomalies, especially congenital 
diaphragmatic hernia.3 In addition, ID, epilepsy, and behavioral problems are frequently 
mentioned.4–6 With respect to the 15q26.1 subregion, the chromodomain helicase 
DNA binding domain 2 (CHD2) gene (OMIM: 602119), originally characterized by 
Woodage et al,7 has been repeatedly reported to play a pivotal role in cerebrocortical 
development.8 Both microdeletions encompassing this gene and de novo loss of 
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function mutations lead to a syndrome characterized by ID 
and epileptic encephalopathy with generalized seizures.9,10
So far, a total of nine patients with ID (seven females 
and two males) has been reported with a genetically proven 
deletion of the CHD2 gene. Of these patients, eight had a 
history of severe forms of epilepsy starting from the young 
age.4–6,11,12
Here, a 15-year-old male with a 15q26.1–q26.2 interstitial 
deletion is described, who was referred to the specialized 
outpatient department for psychopathology and genetics 
because of short-lasting psychotic episodes and problematic 
management of disinhibited behaviors for which over many 
years symptomatic treatment with antipsychotics (ie, halo-
peridol) was ineffective.
Clinical description
The patient is a 15-year-old male of Chinese origin, who was 
adopted at the age of 18 months in a malnourished condi-
tion from an orphanage by his Dutch foster parents. Shortly 
after birth, in the People’s Republic of China, he underwent 
the first surgical correction for bilateral cheilognathopala-
toschisis followed by several reconstructive surgeries in 
the Netherlands up to the age of 5 years. Upon arrival, he 
was referred to a pediatrician of a university hospital for 
evaluation of developmental delay as well as bizarre autis-
tic and disinhibited behaviors. At examination, apart from 
moderate auditory impairment secondary to recurrent upper 
airway infections, mild motor delay was noticed for which 
physical therapy was applied. Full laboratory investiga-
tion according to the Dutch adoption protocol, including 
screening for metabolic disorders, disclosed no abnormali-
ties. Electroencephalogram (EEG) registration revealed focal 
frontocentral abnormalities that were difficult to interpret 
because of muscular artifacts.
At the age of 2 years, a symptomatic treatment with a low 
dose of haloperidol was started because of persisting challeng-
ing behavior. Subsequently, he was extensively examined by 
a child neurologist at the age of 5 years. Weight, length, and 
head circumference were 17.4 kg (-1 standard deviation [SD]), 
110 cm (0 SD), and 46 cm (-2 SD), respectively. No abnor-
malities were found apart from motor overactivity. His atten-
tion was undisturbed, whereas communication was adequate 
with the use of a hearing aid. Since his parents frequently 
noticed brief moments with a blank staring and unrespon-
siveness to his surroundings, EEG recording was performed, 
which showed similar frontal irregularities without, however, 
specific epileptic configurations. A diagnosis of aspecific 
psychomotor retardation was made. Six months later, due to 
aggressive, self-injurious, and autistic behaviors, reevaluation 
by a pediatrician was performed, who advised a more congru-
ent and structured behavioral approach.
During subsequent years, various interventions with antip-
sychotics for behavioral control were implemented, which, 
however, frequently induced unwanted side effects such as dys-
kinesias, akathisia, and facial edema. In this period, intelligence 
testing was performed twice with an interval of 3 years showing 
a total intelligence quotient (IQ) of 55 and a developmental age 
of ~3.6 years (calendar age: 8 years). At the age of 12 years, 
microarray analysis (Agilent 180K oligoarray, amadid 023363 
[Agilent Technologies, Santa Clara, CA, USA]) demonstrated 
an 1.8 Mb interstitial deletion in 15q26.1–q26.2, encompassing 
the CDH2 and RGMA genes that were considered to be etiologi-
cally involved (karyotype: arr[hg19]15q26.1q26.2(93,408,532-
95,188,862)x1; Figure 1). Magnetic resonance imaging scan 
of the brain showed no abnormalities.
In the next 18 months, two short-lasting episodes occurred 
characterized by marked global regression, anxieties, hal-
lucinatory experiences (visual and auditory), as well as 
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Figure 1 Copy number profile of chromosome 15 of the patient obtained by oligoarray-based comparative genomic hybridization (180K platform).
Note: The chromosome 15 copy number imbalance in 15q26.1–q26.2 is shown in detail.
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disinhibited and aggressive behaviors. Treatment with 
haloperidol and promethazine in a twice-daily dose of 1.5 
and 25 mg, respectively, was prescribed with, however, insuf-
ficient efficacy. As a consequence, the patient was referred to 
the specialized outpatient facility for psychopathology and 
genetics for integrative assessment of behavior and psycho-
pathology in the context of the genetic condition. Written 
informed consent has been obtained from the mother of the 
patient. This study has been approved by the Vincent van 
Gogh Institutional Review Board.
Results
At examination, a young male adolescent was seen with 
a status after multiple reconstructive surgical corrections 
for bilateral cheilognathopalatoschisis. No dysmorphias 
were noticed. His behavioral repertoire comprised com-
pulsive elements, hyperactivity, and impulsivity. No major 
psychiatric symptoms could be identified. Detailed heteroan-
amnestic evaluation revealed that, since the age of 13 years, 
two short-lasting psychotic episodes had occurred domi-
nated by anxieties, dysphoric mood swings, threatening and 
disinhibited behaviors, physical aggression, and both visual 
and auditory hallucinations, accompanied by diminished 
consciousness as well as restricted interpersonal contact.
Routine hematological and biochemical laboratory tests 
were all normal. Pharmacogenetic analysis demonstrated no 
abnormalities for CYP2C9 and CYP2C19. For CYP2D6, 
however, a *10/*10 genotype was found that is in accordance 
with a significantly impaired biotransformation capacity.
Extensive neuropsychological assessment (Vineland 
screener,13 VISK14) showed a developmental age of 2 years 
with a discrepant profile (social: 0.8 years; motor and com-
munication: .2.6 years). Formal intelligence testing could 
not be fully performed due to major impairments of attention 
and inhibitory functioning as well as repetitive behaviors. 
The latter was objectivated by proxy ratings of attention and 
executive functioning (BRIEF,15 BADS-DEX16). Assessment 
of psychopathology by means of the psychopathology instru-
ment for mentally retarded adults pointed specifically at 
chaotic, anxious, and generally inadaptive behaviors (total 
score: 32; maximum: 56).17
Based on the aforementioned information, a preliminary 
diagnosis of epilepsy-related recurrent brief psychosis was 
made and it was advised to perform EEG recording. The latter 
revealed that some epileptic paroxysms left frontotemporal 
and sporadic polyspike–wave complexes. For this reason, the 
antiepileptic compound valproic acid was prescribed, whereas 
symptomatic treatment for behavioral control with a low dose 
of haloperidol (1.6 mg daily [gtt]; plasma concentration: 
1 μg/L) was continued. This antiepileptic intervention (600 mg 
valproic acid; plasma concentration: 85 mg/L) resulted in a full 
remission of psychotic symptoms and a gradual normalization 
of behavior to the premorbid level that, apart from incidentally 
occurring odd beliefs, was paralleled by stabilization of mood 
and marked improvement of social adaptation.
Discussion
In the moderately intellectually disabled patient presented 
here, psychotic phenomena appeared to be the result of a 
previously unrecognized absence epilepsy. Treatment with 
valproic acid induced a substantial improvement of his 
behavior while keeping free from further psychotic episodes. 
As stressed by several authors, epilepsy-related psychoses, 
both post- and interictal, are still a clinical challenge to 
recognize and treat appropriately.18,19
The 15q26.1 microdeletion, encompassing among others 
the CHD2 gene, is in general associated with febrile seizures 
starting at early age followed by various epileptic features, 
myoclonic as well as tonic–clonic and absence seizures, 
and not typically clear dysmorphisms.9,10 In the current 
patient, absence epilepsy was only present. Out of a total 
of nine published cases, this type of epilepsy is mentioned 
in two, whereas in one, no epilepsy was present (Table 1). 
As can be inferred, in addition to the published cases, four 
Table 1 reported patients with a 15q26 microdeletion encompassing the CHD2 gene, intellectual disability, and challenging 
behaviorsa
Study Patient 
number
Sex/age 
(years)
Deletion 
size
Dysmorphisms Epilepsy Remarks
Veredice et al4 1 F/2.6 ~5 Mb + +b Congenital hypothyroidism
Dhamija et al5 1 F/9 ~731 kb + +b
Capelli et al6 1 F/6 ~500 kb + + Gate ataxia
also deletion of RGMA
Courage et al11 1 M/25 ~415 kb + + also deletion of RGMA
2 M/21 ~106 kb + + also deletion of RGMA
Chénier et al12 1 F/11 ~191 kb + + auditory neuropathy
2 F/9 ~210 kb + +
(Continued)
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patients are registered in international databases of whom 
one (DECIPHER 304608) was not diagnosed with epilepsy. 
Finally, two patients were detected in large copy-number 
variation studies, but no clinical information about their 
phenotype or presence of epilepsy is provided.
In eight patients, the 15q26.1 deletion also encompassed 
the RGMA gene (OMIM: 607362) that is assumed to be 
involved in immune functionality but not regarded to be of 
clinical significance for ID or epilepsy.20
Conclusion
This case demonstrates the vital importance of detailed ana-
mnesis and careful description of the symptom–cognition–
behavior complex over time, both to ensure early detection 
of epilepsy-related psychopathology, especially in people 
with ID, and to avoid diagnostic misinterpretation and inap-
propriate treatment.
Disclosure
The authors report no conflicts of interests in this work.
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Table 1(Continued)
Study Patient 
number
Sex/age 
(years)
Deletion 
size
Dysmorphisms Epilepsy Remarks
3 F/6 ~78 kb + -
4 F/16 ~237 kb - + also deletion of RGMA
eCarUCa 
database
4,878 M/22 ~106 kb + + also deletion of RGMA
5,121 F/27.5 ~4.2 Mb + + Congenital cardiovascular anomaly
also deletion of RGMA
DeCIpHer 
database
270,487 F/3 ~4.05 Mb ns + also deletion of RGMA
304,608 F/15 ~240 kb ns - also deletion of RGMA
present patient 1 M/15 ~1.8 Mb - + Bilateral cheilognathopalatoschisis
also deletion of RGMA
Notes: aBoth pinto et al21 and Hamdan et al22 report patients with a deletion of the CHD2 gene, who were both identified from large-scale studies on CNVs in patients with 
intellectual disability and/or autism spectrum disorder. No further information is available. bepilepsy reported drug resistance. “+”, present; “-”, absent.
Abbreviations: F, female; M, male; ns, not significant; CNVs, copy number variations; ECARUCA, European cytogeneticists association register of unbalanced chromosome 
aberrations; DeCIpHer, database of genomic variation and phenotype in humans using ensembl resources.
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